BioNTech (NASDAQ:BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

BioNTech has launched global clinical trials for BNT116, an mRNA vaccine designed to treat non-small cell lung cancer. Utilizing the same mRNA technology as Covid-19 vaccines, BNT116 aims to prime ...

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...

Drug Improves Effectiveness of Radiation for Lung Cancer That Has Spread to the Brain Oct. 4, 2024 — The University of Cincinnati's Debanjan Bhattacharya is first author of new research ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Medscape Medical News, June 30, 2023 BioNTech, OncoC4 Start Late-Stage Lung Cancer Drug Trial BioNTech and its US partner OncoC4 say they have started a late-stage study of their lung cancer ...

An analysis of patients with lung metastases from colorectal ... 2024 BioNTech Says FDA Lifts Partial Hold on Its Cancer Drug Trial BioNTech on Monday said the U.S. Food and Drug Administration ...